Abstract
Experimental gene-therapeutic approaches for the prevention of restenosis after balloon angioplasty are the major source of our insight into pathways operative in the process of vascular renarrowing. We now understand that thrombosis and inflammation are the key mechanisms triggering vascular “healing” in response to injury and know a multitude of potential gene-therapeutic strategies to interfere with appositional thrombus formation, proliferation and migration of vascular smooth muscle cells, lesional recruitment of inflammatory cells or excess deposition of extracellular matrix. Thus far, the major limitation for clinical anti-restenotic gene therapy are concerns about the safety and efficacy of vector systems in use for the local overexpression of transgenes, which in turn is one of the most attractive advantages of gene therapy compared to systemic drug therapy. Here, we review the molecular mechanisms operative in postangioplasty restenosis by highlighting their respective gene therapeutic approaches and the current viral and non-viral vector systems.
Keywords: gene therapy, restenosis, balloon angioplasty, inflammation, smooth muscle cell proliferation, adenovirus
Current Vascular Pharmacology
Title: Gene Therapy Approaches for the Prevention of Restenosis
Volume: 2 Issue: 2
Author(s): Christoph W. Kopp and Rainer de Martin
Affiliation:
Keywords: gene therapy, restenosis, balloon angioplasty, inflammation, smooth muscle cell proliferation, adenovirus
Abstract: Experimental gene-therapeutic approaches for the prevention of restenosis after balloon angioplasty are the major source of our insight into pathways operative in the process of vascular renarrowing. We now understand that thrombosis and inflammation are the key mechanisms triggering vascular “healing” in response to injury and know a multitude of potential gene-therapeutic strategies to interfere with appositional thrombus formation, proliferation and migration of vascular smooth muscle cells, lesional recruitment of inflammatory cells or excess deposition of extracellular matrix. Thus far, the major limitation for clinical anti-restenotic gene therapy are concerns about the safety and efficacy of vector systems in use for the local overexpression of transgenes, which in turn is one of the most attractive advantages of gene therapy compared to systemic drug therapy. Here, we review the molecular mechanisms operative in postangioplasty restenosis by highlighting their respective gene therapeutic approaches and the current viral and non-viral vector systems.
Export Options
About this article
Cite this article as:
Kopp W. Christoph and Martin de Rainer, Gene Therapy Approaches for the Prevention of Restenosis, Current Vascular Pharmacology 2004; 2 (2) . https://dx.doi.org/10.2174/1570161043476438
DOI https://dx.doi.org/10.2174/1570161043476438 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Current Pharmaceutical Design Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine Thrombolytic Therapy in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Diffusion Tensor MRI Assessment of Skeletal Muscle Architecture
Current Medical Imaging Biomimetic Synthetic Self-Assembled Hydrogels for Cell Transplantation
Current Topics in Medicinal Chemistry Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology Biochemical Basis of Ischemic Heart Injury and of Cardioprotective Interventions
Current Medicinal Chemistry L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Regulation and Pharmacology of Pacemaker Channels
Current Pharmaceutical Design Biochemical Markers of Renal Function
Current Medicinal Chemistry Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews The Antiplatelet Drug Target in Atherosclerotic Diseases
Cardiovascular & Hematological Disorders-Drug Targets The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology HspB1 Dynamic Phospho-Oligomeric Structure Dependent Interactome as Cancer Therapeutic Target
Current Molecular Medicine Anti-Proliferative Compounds for the Prevention of Restenosis: Anti-Restenotic Mechanisms of Paclitaxel Action
Current Pharmaceutical Design Metabolomics by Imaging; Biochemical-Magnetic Resonance Correlation: What We Learn from Combined Data of Magnetic Resonance Spectroscopy, NMR Spectroscopy, Clinical Chemistry and Tissue Content Analysis? Major Bottlenecks in Diagnosis
Recent Patents on Medical Imaging Structural Basis for the Design of PPAR-γ Ligands: A Survey on Quantitative Structure- Activity Relationships
Mini-Reviews in Medicinal Chemistry